Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIZE extension study of sotatercept in combined post- and precapillary pulmonary hypertension associated with HFpEF
MOH_2025-03-27_013905Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sotatercept in pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Merck & Co. Primary endpoint: Long-term safety and tolerability of sotatercept. Started Mar 2025; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on MOH_2025-03-27_013905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-27_013905.